- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Conduct BE study with innovator drug as reference product: CDSCO Panel Tells Synokem on FDC Torsemide plus Eplerenone
New Delhi: After reviewing the bioequivalence (BE) study report presented by Synokem Pharmaceutical for the fixed-dose combination Torsemide IP 10mg/20mg plus Eplerenone IP 25mg/25mg film-coated tablet, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended that the firm should conduct BE study with individual innovator drugs...
New Delhi: After reviewing the bioequivalence (BE) study report presented by Synokem Pharmaceutical for the fixed-dose combination Torsemide IP 10mg/20mg plus Eplerenone IP 25mg/25mg film-coated tablet, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended that the firm should conduct BE study with individual innovator drugs as a reference product and submit the BE protocol to the committee.
This came after Synokem Pharmaceutical presented its proposal and a BE study report before the committee.
The committee noted that the firm has not conducted the BE study with individual innovator drugs as a reference product.
Torsemide belongs to the group of medicines called loop diuretics (water pills). This medicine works by acting on the kidneys to increase the flow of urine. Torsemide is used to help treat fluid retention (edema) and swelling that is caused by congestive heart failure, liver disease, and kidney disease. It belongs to the group of medicines called loop diuretics (water pills). This medicine works by acting on the kidneys to increase the flow of urine.
Eplerenone belongs to the general class of medicines called antihypertensives. It is used alone or with other medicines to treat high blood pressure (hypertension). This medicine is also used to treat congestive heart failure (CHF) after a heart attack.
Eplerenone selectively binds to the mineralocorticoid receptor, thereby blocking the binding of aldosterone and thus inhibiting sodium reabsorption and other deleterious aldosterone-mediated mechanisms.
At the SEC meeting for Cardiovascular and Renal held on 22nd November 2023, the expert panel reviewed the proposal presented by the drug major Synokem Pharmaceutical along with the BE study report of the FDC Torsemide plus Eplerenone film coated table.
The committee took note of the fact that the company had not used specific innovative medications as a reference product in the BE study.
After detailed deliberation, the committee recommended that the firm should conduct a BE study with individual innovator drugs as a reference product.
Accordingly, the expert panel suggested that the firm should submit the BE protocol to CDSCO for further review.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751